Cover Image
市場調查報告書

全球非小細胞癌(NSCLC)市場未來展望:新治療方法的治療能力強化,和促進競爭激烈的市場上的成長

Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market

出版商 GBI Research 商品編碼 310296
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
全球非小細胞癌(NSCLC)市場未來展望:新治療方法的治療能力強化,和促進競爭激烈的市場上的成長 Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market
出版日期: 2014年07月31日 內容資訊: 英文
簡介

全球非小細胞癌(NSCLC)治療藥的市場,推算2013年達到51億美元,2020年達到79億美元的規模,其間的年複合成長率(CAGR)為6.6%。以扁平表皮癌症作為標的新治療方法的開發與普及,成為市場成長的主要推動因素。但,雖然有幾個有前途的開發中產品,臨床實驗的整體進展仍停留在初期階段。

本報告提供全球非小細胞癌(NSCLC)治療方法的相關市場分析、疾病概要和主要的治療方法、已上市產品概要(安全性、功效等)、現在正在開發的治療藥的開發平台資訊、地區整體及主要國的市場趨勢預測(今後8年的預測值)、產業聯盟的動向等調查。

第1章 目錄

第2章 簡介

  • 疾病概要
  • 流行病學
  • 病因、病理生理學
    • 腺癌症
    • 扁平表皮癌
    • 大細胞癌
    • 免疫療法
  • 症狀
  • 診斷
  • 預後
  • 治療方法
    • 治療流程
    • 一線治療
    • 維持療法
    • 二線治療
    • 三線治療
    • 輔助性治療

第3章 已上市產品

  • 概要
  • 各種化療
    • 順鉑(cisplatin)
    • Carboplatin
    • Vinorelbine
    • Paclitaxel
    • Docetaxel
    • 健擇
  • Alimta:Eli Lilly
  • Abraxane:Celgene Corporation
  • Tarceva:Roche
  • Iressa:AstraZeneca
  • Gilotrif:Boehringer Ingelheim
  • Xalkori:Pfizer
  • Avastin(Bevacizumab):Roche
  • 已上市產品的熱圖
  • 結論

第4章 非小細胞癌(NSCLC)的開發中產品

  • 概要
  • 開發中產品的作用機制
  • 臨床實驗資訊
    • 失敗率
    • 臨床實驗期間
    • 臨床實驗規模
    • 臨床實驗的主要試驗指標
  • 臨床實驗最後階段的開發中產品簡介
    • Custirsen:Teva Pharmaceutical Industries
    • Halaven:Eisai
    • Dacomitinib:Pfizer
    • Vargatef:Boehringer Ingelheim
    • Necitumumab:Eli Lilly
    • Ganetespib:Synta Pharmaceuticals
    • Zykadia:Novartis
    • Yervoy:Bristol Myers Squibb
    • Nivolumab:小野藥品工業/Bristol-Myers Squibb
    • MK-3475:Merck
    • RG7446:Roche
    • Cyramza:Eli Lilly
    • Tavocept:BioNumerik Pharmaceuticals
    • Tecemotide:Merck Serono
    • Tertomotide:KAEL-GemVax
    • Lucanix:NovaRx Corporation
    • Bevacizumab的生技仿製藥:複數企業
  • 安全性、功效的熱圖
  • 結論
    • 產品競爭力的組成架構
    • 未來的治療流程

第5章 市場趨勢的預測

  • 各地區的市場趨勢
    • 全球市場
    • 北美
    • 歐洲主要5個國家
    • 日本
  • 市場促進、阻礙因素

第6章 策略性企業聯盟的動向

  • 主要的共同開發契約(共5件)
  • 主要的授權合約(共5件)

第7章 附錄

圖表一覽

目錄
Product Code: GBIHC338MR

GBI Research, a leading business intelligence provider, has released its latest research report, "Non-Small Cell Lung Cancer Market to 2020 - New Therapies to Enhance Treatment Segmentation and Drive Growth in an Increasingly Competitive Market". The value of the Non-Small Cell Lung Cancer (NSCLC) market is expected to increase significantly over the forecast period across the leading eight developed nations, from $5.1 billion in 2013 to $7.9 billion in 2020. This equates to a Compound Annual Growth Rate (CAGR) of 6.6%. Growth will be driven by novel therapies entering the squamous cell carcinoma market segment, which is currently lacking effective treatment, unlike the non-squamous market segment.

The report focuses on the increasing differentiation between the three main NSCLC subtypes: squamous cell, adenocarcinoma, and large cell carcinoma. Common genetic and molecular aberrations within these histologies are being extensively researched and targeted by novel therapeutics and so the treatment algorithm between histological subtypes is forecast to become more differentiated over the forecast period. Most notably, patients with squamous cell carcinoma are set to benefit from crucial first- and second-line therapies in the form of Yervoy (ipilimumab) and nivolumab, having relied on generic chemotherapy for the past decade. Non-squamous patients, on the other hand, have several successful histology-specific therapies, such as Alimta (pemetrexed), and mutation-specific therapies, such as Tarceva (erlotinib), that are already marketed. New second-line entrants will create a crowded and competitive environment. The generic erosion of market leaders Alimta and Tarceva late in the forecast period will make this a tough environment for new products that have shown only minor improvements in safety or efficacy.

Despite the potential of targeted therapies and the identification of several promising molecular targets, the development of these products remains in the early-stage pipeline. Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations are likely to remain the only identified intracellular molecular aberrations targeted by marketed products, both of which are mainly found in adenocarcinoma tumors. Instead, the late-stage pipeline is primarily occupied by immunotherapies, which still offer a greater degree of specificity than chemotherapies; however, they initiate tumor destruction via the immune system. Necitumumab, Yervoy and nivolumab are all Phase III immunotherapies expected to reach the market in the forecast period, each with a different target.

Resistance to targeted therapies is a significant issue in the NSCLC market as the onset of acquired resistance to therapies such as Tarceva or Xalkori (crizotinib) has greatly reduced their potential. Despite the limited late-stage pipeline activity with new molecular targets, there are new drugs targeting EGFR and ALK that may combat resistance, thereby increasing the time frame in which patients are treatable with targeted therapy. Gilotrif (afatinib) is a recently launched EGFR inhibitor with a novel mechanism of action that may delay the onset of resistance, and Zykadia (LDK378) is an ALK inhibitor in the late-stage pipeline that is set to treat Xalkori-resistant patients.

Scope

The report assesses the current NSCLC market and predicts market trends to 2020, analyzing key drivers and barriers.The areas covered include -

  • A disease introduction, which defines the disease and looks at symptoms, diagnosis and treatment
  • Analysis of the NSCLC marketed landscape, including a comparison of the efficacy and safety of the most prominent brands, as well as the unmet needs of NSCLC treatment
  • Detailed analysis of the NSCLC pipeline, covering among other parameters, drug distribution by Phase, molecule type and mechanism of action. The NSCLC clinical trial landscape is analyzed with particular emphasis on failure rates across different trial Phases, as well as the trends in clinical trial size, duration and primary endpoint. This section also includes profiles and single product forecasts for the most promising pipeline drugs.
  • An epidemiological forecast of the major NSCLC markets, in which projected values include total and treated populations
  • An in-depth forecasting model for the NSCLC market, which considers the current marketed therapies in addition to the potential entry of new products to the market. The model comprises a projected outcome with high and low variance results depending on the potential performance of pipeline therapies.
  • Analysis of strategic consolidations within the NSCLC indication, including co-development and licensing agreements
  • An overview of the drivers of and barriers to the NSCLC market

Reasons to buy

  • The report will enable clients to develop a strong understanding of NSCLC as a disease and as a market. The current therapeutic needs and future market trends will highlight opportunities and the scope of competition between NSCLC therapeutics. Primarily, the report will allow clients to -
  • Understand the NSCLC pipeline and the clinical needs that it is addressing, particularly the ways in which histology affects treatment options and where in the treatment algorithm new products will be positioned, as well as where unmet needs remain
  • Develop their knowledge of key products that may enter the market before 2020. Detailed profiles of these products are provided, with a focus on their clinical trial performance, as well as how they can be incorporated into the NSCLC treatment plan and what competition they face.
  • Assess the risk associated with NSCLC product development profiled by molecule type and mechanism of action and compared with both industry and therapy-area averages. In addition, data analyses offer a more detailed understanding of the trends in both trial size and duration for specific mechanisms of action or molecule types. The primary endpoint analysis infers trends in trial design within the therapy area, as well as the endpoints that are the best indicators of success.
  • Identify patterns of growth in the NSCLC market over the forecast period and understand the underlying causes, as well as observing the contributions made by each major market and/or late-stage pipeline drug to this growth.

Abstract

Pipeline Entries to Drive NSCLC Market Growth

The Non-Small Cell Lung Cancer (NSCLC) market will undergo considerable growth from $5.1 billion in 2013 to $7.9 billion in 2020 at a Compound Annual Growth Rate (CAGR) of 6.6%. The added value will be derived from an abundance of new product launches relatively early in the forecast period. Many of these therapies will target the second line of treatment; both the first-line treatment of patients with non-squamous histology and the maintenance setting will remain relatively unchanged by 2020. New second-line therapies include immunostimulants such as ramucirumab and nivolumab, which have shown clinical benefits, but which will face difficulties due to the increasingly crowded second-line setting. Currently, pharmaceutical treatment is limited to late-stage patients. However, vaccine therapies such as Lucanix (belagenpumatucel-L) will launch in the forecast period, for patients with stage II or IIIA NSCLC, in the currently sparse adjuvant setting. Although vaccine treatments have been unsuccessful so far in NSCLC - the most recent example being GSK's MAGE-A3 vaccine failing its Phase III trial - Lucanix has shown large improvements to survival rates in its initial clinical trials.

Monoclonal Antibodies to Diversify Squamous Cell Treatment

Over the forecast period to 2020, several new additions to the NSCLC treatment paradigm will transform the treatment landscape. Many of these will be monoclonal Antibodies (mAbs), which instigate an immune response to the tumor rather than directly affecting cancer cells. Crucially, some of these mAbs will be indicated for patients with squamous cell histology, whose current treatment options are very limited and primarily consist of chemotherapy. Squamous cell histology accounts for approximately 30% of the NSCLC population, and pipeline products, such as Yervoy (ipilimumab) in the first-line treatment and nivolumab in the second-line, will add greater diversity to the treatment algorithm, with both having shown clinical benefits in early-stage trials. Access to these premium treatments in this under-represented segment will be one of the primary drivers for growth in the overall NSCLC market.

Efforts are being made to understand the molecular characterization of NSCLC tumors in order to identify cancer-cell-specific targets for therapy, based on the success of targeted therapies Tarceva (erlotinib) and Xalkori (crizotinib). However, novel therapies targeting these molecules, such as Kirsten Rat Sarcoma viral oncogene homolog (KRAS), have so far been unsuccessful in the late-stage pipeline, meaning that the range of mutant signal pathway molecules targeted by therapy will remain largely unchanged over the forecast period and mAb immunotherapies targeting cancer or T-cell antigens will have a much larger impact than small-molecule-targeted signal inhibitors.

Major Patents to Expire Late in Forecast Period

Patents for Alimta (pemetrexed), Avastin (bevacizumab), Tarceva, and Iressa (gefitinib) will all expire between 2017 and 2020. Alimta is a vital therapy for non-squamous patients and is in many cases the preferred course of treatment, combined with cisplatin. Generic availability following patent expiry in 2017 will make non-squamous chemotherapy cheaper, although the market value will ultimately continue to rise despite generic erosion, due to successful pipeline entrants. Tarceva is widely used in first-line Epidermal Growth Factor Receptor (EGFR) positive patients, and generally in the second-line setting. Its patent will not expire until 2020 however, meaning that the effects will not be felt during the 2014-2020 forecast period. Iressa is not widely used, and therefore the patent expiration in 2017 will have little impact.

Early Diagnosis to Remain Uncommon

The vast majority (70%) of NSCLC cases are diagnosed in stage IIIB or IV, at which point surgical resection is not possible, making pharmacological intervention the best course of action. The number of treatment settings for late-stage patients, specifically first-line, second-line and maintenance, adds significant value to the market. Should the number of early diagnoses increase, fewer patients would require extensive chemotherapy or targeted therapy, meaning that the market would decrease. However, improvements to the diagnosis of NSCLC are limited. Identifying Stage I-IIIA tumors remains difficult, despite the identification of high-risk groups, such as smokers. Over the forecast period, the characterization of tumors will likely improve, and more potential biomarkers will be identified. Screening and diagnostic technology will not change significantly over the forecast period however, meaning the number of patients diagnosed in early stages will remain at approximately 30%.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Disease Introduction
  • 2.2. Epidemiology
  • 2.3. Etiology and Pathophysiology
    • 2.3.1. Adenocarcinoma
    • 2.3.2. Squamous Cell Carcinoma
    • 2.3.3. Large Cell Carcinoma
    • 2.3.4. Immunotherapy
  • 2.4. Symptoms
  • 2.5. Diagnosis
  • 2.6. Prognosis
  • 2.7. Treatment
    • 2.7.1. Treatment Algorithm
    • 2.7.2. First-Line Treatment
    • 2.7.3. Maintenance Therapy
    • 2.7.4. Second-Line Therapy
    • 2.7.5. Third-Line Therapy
    • 2.7.6. Adjuvant Therapy

3. Marketed Products

  • 3.1. Overview
  • 3.2. Chemotherapies - Various
    • 3.2.1. Cisplatin
    • 3.2.2. Carboplatin
    • 3.2.3. Vinorelbine
    • 3.2.4. Paclitaxel
    • 3.2.5. Docetaxel
    • 3.2.6. Gemcitabine
  • 3.3. Alimta - Eli Lilly
  • 3.4. Abraxane - Celgene Corporation
  • 3.5. Tarceva - Roche
  • 3.6. Iressa - AstraZeneca
  • 3.7. Gilotrif - Boehringer Ingelheim
  • 3.8. Xalkori - Pfizer
  • 3.9. Avastin (bevacizumab) - Roche
  • 3.10. Marketed Products Heatmap
  • 3.11. Conclusion

4. NSCLC Pipeline

  • 4.1. Overview
  • 4.2. Mechanisms of Action in the Pipeline
  • 4.3. Clinical Trials
    • 4.3.1. Failure Rate
    • 4.3.2. Clinical Trial Duration
    • 4.3.3. Clinical Trial Size
    • 4.3.4. Clinical Trial Primary Endpoints
  • 4.4. Late-Stage Pipeline Product Profiles
    • 4.4.1. Custirsen - Teva Pharmaceutical Industries
    • 4.4.2. Halaven - Eisai
    • 4.4.3. Dacomitinib - Pfizer
    • 4.4.4. Vargatef - Boehringer Ingelheim
    • 4.4.5. Necitumumab - Eli Lilly
    • 4.4.6. Ganetespib - Synta Pharmaceuticals
    • 4.4.7. Zykadia- Novartis
    • 4.4.8. Yervoy - Bristol Myers Squibb
    • 4.4.9. Nivolumab - Ono Pharmaceuticals/Bristol-Myers Squibb
    • 4.4.10. MK-3475 - Merck
    • 4.4.11. RG7446 - Roche
    • 4.4.12. Cyramza- Eli Lilly
    • 4.4.13. Tavocept - BioNumerik Pharmaceuticals
    • 4.4.14. Tecemotide - Merck Serono
    • 4.4.15. Tertomotide - KAEL-GemVax
    • 4.4.16. Lucanix - NovaRx Corporation
    • 4.4.17. Bevacizumab Biosimilar - Various
  • 4.5. Safety and Efficacy Heatmap
  • 4.6. Conclusion
    • 4.6.1. Product Competitiveness Framework
    • 4.6.2. Future Treatment Algorithm

5. Market Forecast

  • 5.1. Geographical Markets
    • 5.1.1. Global Markets
    • 5.1.2. North America
    • 5.1.3. Top Five EU Countries
    • 5.1.4. Japan
  • 5.2. Drivers and Barriers
    • 5.2.1. Drivers
    • 5.2.2. Barriers

6. Strategic Consolidations

  • 6.1. Major Co-Development deals
    • 6.1.1. Merck Enters into Co-Development Agreement with Endocyte
    • 6.1.2. Exelixis Enters into a Co-Development Agreement with Genentech
    • 6.1.3. CancerVax Enters into an Agreement with CIMAB and YM Biosciences
    • 6.1.4. SFJ Pharma Enters into Co-Development Agreement with Pfizer for Dacomitinib
    • 6.1.5. OxOnc Development Enters into Co-Development Agreement with Pfizer for Crizotinib
  • 6.2. Major Licensing Deals
    • 6.2.1. Merck Serono Enters into Licensing Agreement with Ono Pharma
    • 6.2.2. Astellas Pharma Enters into Licensing Agreement with Aveo Pharma
    • 6.2.3. Clovis Oncology Enters into a Licensing Agreement with Avila Therapeutics
    • 6.2.4. Novartis Enters into Licensing Agreement with Antisoma
    • 6.2.5. Cell Therapeutics Enters into Licensing Agreement with Novartis

7. Appendix

  • 7.1. References
  • 7.2. Market Definition
  • 7.3. Abbreviations
    • 7.3.1. Research Methodology
    • 7.3.2. Secondary Research
    • 7.3.3. Marketed Product Profiles
    • 7.3.4. Late-Stage Pipeline Candidates
    • 7.3.5. Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
    • 7.3.6. Product Competitiveness Framework
    • 7.3.7. Pipeline Analysis
    • 7.3.8. Forecasting Model
    • 7.3.9. Deals Data Analysis
  • 7.4. Contact Us
  • 7.5. Disclaimer

List of Tables

  • Table 1: Non-Small Cell Lung Cancer Market, Global, Tumor Node Metastasis Classification, 2014
  • Table 2: Non-Small Cell Lung Cancer Market, Global, Eastern Co-operative Oncology Group Criteria, 2014
  • Table 3: Non-Small Cell Lung Cancer Market, Global, Treatment Options, 2014
  • Table 4: Non-Small Cell Lung Cancer Market, Global, Stage IIIB-IV Treatment Options, 2014
  • Table 5: Non-Small Cell Lung Cancer Market, Global, Chemotherapy Treatment, 2014
  • Table 6: Non-Small Cell Lung Cancer Market, Global, Chemotherapy Treatment by Regimen, 2014
  • Table 7: Non-Small Cell Lung Cancer Market, Global, Pipeline, Preclinical, 2014
  • Table 8: Non-Small Cell Lung Cancer Market, Global, Pipeline, Phase I, 2014
  • Table 9: Non-Small Cell Lung Cancer Market, Global, Pipeline, Phase II, 2014
  • Table 10: Non-Small Cell Lung Cancer Market, Global, Pipeline, Phase III, 2014
  • Table 11: Non-Small Cell Lung Cancer Market, Global, Pipeline, Pre-registration, 2014
  • Table 12: Non-Small Cell Lung Cancer Market, Global, Pipeline, Undisclosed, 2014
  • Table 13: Non-Small Cell Lung Cancer Market, Global, Market Forecast, 2013-2020
  • Table 14: Non-Small Cell Lung Cancer Market, US, Market Forecast, 2013-2020
  • Table 15: Non-Small Cell Lung Cancer Market, Canada, Market Forecast, 2013-2020
  • Table 16: Non-Small Cell Lung Cancer Market, UK, Market Forecast, 2013-2020
  • Table 17: Non-Small Cell Lung Cancer Market, France, Market Forecast, 2013-2020
  • Table 18: Non-Small Cell Lung Cancer Market, Germany, Market Forecast, 2013-2020
  • Table 19: Non-Small Cell Lung Cancer Market, Italy, Market Forecast, 2013-2020
  • Table 20: Non-Small Cell Lung Cancer Market, Spain, Market Forecast, 2013-2020
  • Table 21: Non-Small Cell Lung Cancer Market, Japan, Market Forecast, 2013-2020

List of Figures

  • Figure 1: Non-Small Cell Lung Cancer Market, Global, Molecular Characteristic Frequency (%), 2014
  • Figure 2: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Late-Stage Treatment Algorithm, 2014
  • Figure 3: Non-Small Cell Lung Cancer Market, Global, Squamous Late-Stage Treatment Algorithm, 2014
  • Figure 4: NSCLC, Global, Marketed Products Heatmap, 2013
  • Figure 5: Non-Small Cell Lung Cancer, Global, Pipeline Summary, 2014
  • Figure 6: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Overview, 2014
  • Figure 7: Non-Small Cell Lung Cancer, Global, Pipeline Mechanisms of Action Breakdown, 2014
  • Figure 8: Non-Small Cell Lung Cancer, Global, Clinical Trial Attrition Rates (%), 2006-2014
  • Figure 9: Non-Small Cell Lung Cancer, Global, Clinical Trial Mechanism of Action Failure Rates by Phase (%), 2006-2014
  • Figure 10: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration (months), 2006-2013
  • Figure 11: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Molecule Type (months), 2006-2013
  • Figure 12: Non-Small Cell Lung Cancer, Global, Clinical Trial Duration by Mechanism of Action (months), 2006-2013
  • Figure 13: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product (participants), 2006-2013
  • Figure 14: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Molecule Type (participants), 2006-2013
  • Figure 15: Non-Small Cell Lung Cancer, Global, Clinical Trial Size per Product by Mechanism of Action (months), 2006-2013
  • Figure 16: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoints, 2006-2013
  • Figure 17: Non-Small Cell Lung Cancer, Global, Clinical Trial Primary Endpoint Combinations by Phase (%), 2006-2013
  • Figure 18: Non-Small Cell Lung Cancer Pipeline, Global, Custirsen Annual Sales ($m), 2018-2020
  • Figure 19: Non-Small Cell Lung Cancer Pipeline, Global, Halaven Annual Sales ($m), 2016-2020
  • Figure 20: Non-Small Cell Lung Cancer Pipeline, Global, Dacomitinib Annual Sales ($m), 2014-2020
  • Figure 21: Non-Small Cell Lung Cancer Pipeline, Global, Vargatef Annual Sales ($m), 2015-2020
  • Figure 22: Non-Small Cell Lung Cancer Pipeline, Global, Necitumumab Annual Sales ($m), 2015-2020
  • Figure 23: Non-Small Cell Lung Cancer Pipeline, Global, Ganetespib Annual Sales ($m), 2016-2020
  • Figure 24: Non-Small Cell Lung Cancer Pipeline, Global, Zykadia Annual Sales ($m), 2014-2020
  • Figure 25: Non-Small Cell Lung Cancer Pipeline, Global, Yervoy Annual Sales ($m), 2015-2020
  • Figure 26: Non-Small Cell Lung Cancer Pipeline, Global, Nivolumab Annual Sales ($m), 2015-2020
  • Figure 27: Non-Small Cell Lung Cancer Pipeline, Global, Cyramza Annual Sales ($m), 2015-2020
  • Figure 28: Non-Small Cell Lung Cancer Pipeline, Global, Tavocept Annual Sales ($m), 2017-2020
  • Figure 29: Non-Small Cell Lung Cancer Pipeline, Global, Tertomotide Annual Sales ($m), 2017-2020
  • Figure 30: Non-Small Cell Lung Cancer Pipeline, Global, Lucanix Annual Sales ($m), 2016-2020
  • Figure 31: Non-Small Cell Lung Cancer , Global, Safety and Efficacy Heatmap, 2013
  • Figure 32: Non-Small Cell Lung Cancer , Global, Marketed Products Heatmap, 2013
  • Figure 33: Non-Small Cell Lung Cancer Market, Global, Product Competitiveness Framework, 2014
  • Figure 34: Non-Small Cell Lung Cancer Market, Global, Non-Squamous Future Treatment Algorithm 2020
  • Figure 35: Non-Small Cell Lung Cancer Market, Global, Squamous Future Treatment Algorithm
  • Figure 36: Non-Small Cell Lung Cancer Market, Global, Treatment Patterns ('000), 2013-2020
  • Figure 37: Non-Small Cell Lung Cancer Market, Global, Market Size ($bn), 2013-2020
  • Figure 38: Non-Small Cell Lung Cancer Market, North America, Treatment Usage Patterns ('000), 2013-2020
  • Figure 39: Non-Small Cell Lung Cancer Market, North America, Annual Cost of Treatment ($), 2013-2020
  • Figure 40: Non-Small Cell Lung Cancer Market, North America, Market Size, 2013-2020
  • Figure 41: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Treatment Patterns ('000), 2013-2020
  • Figure 42: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Annual Cost of Treatment ($), 2013-2020
  • Figure 43: Non-Small Cell Lung Cancer Market, Top Five EU Countries, Market Size ($m), 2013-2020
  • Figure 44: Non-Small Cell Lung Cancer Market, Japan, Treatment Usage Patterns ('000), 2013-2020
  • Figure 45: Non-Small Cell Lung Cancer Market, Japan, Annual Cost of Treatment ($), 2013-2020
  • Figure 46: Non-Small Cell Lung Cancer Market, Japan, Market Size ($bn), 2013-2020
  • Figure 47: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Region, 2006-2014
  • Figure 48: Non-Small Cell Lung Cancer, Global, Number of Co-Development Deals, 2006-2014
  • Figure 49: Non-Small Cell Lung Cancer, Global, Co-Development Deals by Phase, 2006-2014
  • Figure 50: Non-Small Cell Lung Cancer, Global, Licensing Deals by Region, 2006-2014
  • Figure 51: Non-Small Cell Lung Cancer, Global, Number of Licensing Deals, 2006-2014
  • Figure 52: Non-Small Cell Lung Cancer, Global, Licensing Deals by Phase, 2006-2014
Back to Top